Optimizing Short Bowel Syndrome Management in Rural and Underserved Settings: Patient Insight and Collaborative Pathways for Delivering Evidence-Based Care
August 31, 2023
August 31, 2024
This activity is provided by Postgraduate Institute for Medicine and RME Collaborative.
This online program is recorded content from the live session at Rural Health Clinical Congress Spring 2023 and is co-supported by independent medical education grants from AbbVie, Inc.; Bristol Myers Squibb; Pfizer and Myovant Sciences, Inc.; Regeneron Pharmaceuticals, Inc. and Sanofi; and Takeda Pharmaceuticals U.S.A., Inc. This activity is supported by an independent medical education grant from Takeda Pharmaceuticals U.S.A., Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Contact Hour (0.50 contact hour of pharmacotherapy credit)
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.
Short bowel syndrome (SBS) is a rare malabsorptive disorder that results in significant morbidity and mortality and reduced quality of life. Patients with the condition are at risk for a variety of complications, some due to the condition itself and others resulting from long-term use of parenteral nutrition. Management is therefore complex and requires a multidisciplinary approach, but available expertise is limited, particularly in rural and underserved areas where primary care clinicians may be the leading providers of care. In this activity, expert faculty will review the efficacy and safety of available pharmacologic therapies for short bowel syndrome and the role of pathophysiology in guiding treatment decisions. Strategies to improve collaboration with the interdisciplinary team to reduce disparities in rural and underserved settings will also be discussed.
This enduring activity is a recorded session from Rural Health Clinical Congress Spring 2023 that took place on May 20, 2023.
Upon completion of this activity, participants should be better able to:
- Describe the pathophysiology and associated risk factors of short bowel syndrome
- Assess available pharmacologic options for patients with short bowel syndrome
- Apply individualized patient-centered strategies for the management of short bowel syndrome to reduce the need for parenteral support and improve clinical outcomes and quality of life
- Utilize evidence-based strategies to improve access to care and interdisciplinary management of patients with short bowel syndrome who reside in rural and underserved communities
John K. DiBaise, MD
Professor of Medicine
Mayo Clinic School of Medicine
Consultant, Division of Gastroenterology and Hepatology
Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
he Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.50 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
John K. DiBaise, MD, has disclosed the following relevant financial relationships: grant/research support from Zealand Pharmaceuticals; consultant/advisory board member for Baxter Healthcare, Napo Pharmaceuticals, Inc., NorthSea Therapeutics, and Takeda Pharmaceuticals.
Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
Instructions for Participation and Credit
This activity is offered at no cost to participants. To receive CME credit, participants must:
- Read the CME/CE information, including learning objectives and disclosure statements.
- Complete the pre-test.
- View the online activity.
- Complete the post-test and evaluation form.
A post-test score of 67% or higher is required to obtain credit. Your certificate will be made available for immediate download.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.
There is no fee for this educational activity.
For general information or questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or firstname.lastname@example.org.
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at email@example.com.